BioCentury
ARTICLE | Clinical News

ABX10241: Preliminary Phase I data

October 11, 2004 7:00 AM UTC

Preliminary data from a double-blind, dose-escalation, U.S. Phase I trial in 17 patients showed that ABX10241 was well tolerated and gave a dose-dependent supression of parathyroid hormone. Patients r...